Indicated prevention is currently one of the most promising approaches to fight the individual and societal burden associated with psychosis, and particularly schizophrenia. Though the number of early intervention studies is still limited, encouraging results have already been reported from pharmacological and psychotherapeutic trials. Furthermore, it has become clear that persons characterized by current at-risk criteria are already ill and do not only need preventive intervention to avoid a possible future outcome, but also treatment for current symptoms. While first early intervention studies had been modelled on treatments for full-blown psychosis, a recent study of Omega-3 fatty acids in preventing transition and improving current symptoms in ultra-high risk subjects indicated that it may be possible to develop benign interventions particularly for the at-risk state, independent of their effectiveness in manifest disease states.